diagnosis_age,american_joint_committee_on_cancer_metastasis_stage_code,neoplasm_disease_lymph_node_stage_american_joint_committee_on_cancer_code,neoplasm_disease_stage_american_joint_committee_on_cancer_code,american_joint_committee_on_cancer_tumor_stage_code,cancer_type_detailed,cent_17_copy_number,disease_free_status,er_positivity_scale_other,er_positivity_scale_used,er_status_by_ihc,er_status_ihc_percent_positive,ethnicity_category,first_surgical_procedure_other,fraction_genome_altered,her_2_and_cent_17_cells_count,her_2_and_cent_17_scale_other,her_2_cent_17_ratio,her_2_copy_number,her_2_fish_method,her_2_fish_status,her_2_ihc_percent_positive,her_2_ihc_score,her_2_positivity_method_text,her_2_positivity_scale_other,neoplasm_histologic_type_name,tumor_other_histologic_subtype,neoadjuvant_therapy_type_administered_prior_to_resection_text,prior_cancer_diagnosis_occurence,icd_10_classification,ihc_her_2,ihc_score,primary_lymph_node_presentation_assessment_ind_3,positive_finding_lymph_node_hematoxylin_and_eosin_staining_microscopy_count,positive_finding_lymph_node_keratin_immunohistochemistry_staining_method_count,lymph_node_s_examined_number,margin_status_reexcision,menopause_status,metastatic_site,metastatic_site_other,metastatic_tumor_indicator,first_pathologic_diagnosis_biospecimen_acquisition_method_type,first_pathologic_diagnosis_biospecimen_acquisition_other_method_type,micromet_detection_by_ihc,mutation_count,new_neoplasm_event_post_initial_therapy_indicator,nte_cent_17_her_2_ratio,nte_er_ihc_intensity_score,nte_er_status,nte_er_status_ihc_positive,nte_her_2_fish_status,nte_her_2_positivity_ihc_score,nte_her_2_status,nte_her_2_status_ihc_positive,nte_pr_ihc_intensity_score,nte_pr_status_by_ihc,nte_pr_status_ihc_positive,oct_embedded,oncotree_code,overall_survival_status,disease_surgical_margin_status,adjuvant_postoperative_pharmaceutical_therapy_administered_indicator,primary_tumor_site,tissue_prospective_collection_indicator,pr_positivity_define_method,pr_positivity_ihc_intensity_score,pr_positivity_scale_other,pr_positivity_scale_used,pr_status_by_ihc,pr_status_ihc_percent_positive,race_category,did_patient_start_adjuvant_postoperative_radiotherapy,tissue_retrospective_collection_indicator,number_of_samples_per_patient,sample_type,sex,staging_system,staging_system_1,surgery_for_positive_margins,surgery_for_positive_margins_other,surgical_procedure_first,tissue_source_site,tmb_nonsynonymous,person_neoplasm_status,Cluster
85.0,M0,N1,Stage IIB,T2,Breast Invasive Ductal Carcinoma,51,0:DiseaseFree,nan,nan,Negative,nan,NOT HISPANIC OR LATINO,nan,1756.0,30.0,nan,16.3,816,nan,Positive,nan,2.0,nan,nan,Infiltrating Ductal Carcinoma,nan,No,No,C50.9,Equivocal,nan,YES,1.0,nan,13.0,nan,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),nan,nan,NO,Core needle biopsy,nan,NO,27.0,nan,nan,nan,nan,nan,nan,nan,nan,nan,nan,nan,nan,VERDADERO,IDC,0:LIVING,Negative,nan,Right Upper Outer Quadrant,YES,nan,nan,nan,nan,Negative,nan,WHITE,nan,NO,1,Primary,Female,Sentinel lymph node biopsy plus axillary dissection,nan,nan,nan,Lumpectomy,A2,933333333.0,TUMOR FREE,Cluster 1
62.0,M0,N1a,Stage IIB,T2,Breast Invasive Ductal Carcinoma,nan,0:DiseaseFree,nan,nan,Positive,60-69%,NOT HISPANIC OR LATINO,nan,6388.0,nan,nan,7.0,nan,nan,Positive,nan,3.0,nan,nan,Infiltrating Ductal Carcinoma,nan,No,No,C50.9,Positive,nan,nan,1.0,0.0,23.0,nan,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),nan,nan,nan,Core needle biopsy,nan,YES,164.0,nan,nan,nan,nan,nan,nan,nan,nan,nan,nan,nan,nan,VERDADERO,IDC,0:LIVING,Negative,nan,Right Upper Outer Quadrant,NO,nan,nan,nan,nan,Negative,<10%,WHITE,nan,YES,1,Primary,Female,Sentinel lymph node biopsy plus axillary dissection,nan,nan,nan,Lumpectomy,A2,5466666667.0,TUMOR FREE,Cluster 1
77.0,M0,N0 (i-),Stage IIA,T2,Breast Invasive Ductal Carcinoma,2,0:DiseaseFree,nan,nan,Positive,20-29%,NOT HISPANIC OR LATINO,nan,1807.0,nan,nan,11.0,21,nan,Positive,nan,3.0,nan,nan,Infiltrating Ductal Carcinoma,nan,No,No,C50.9,Positive,nan,nan,0.0,nan,3.0,nan,nan,nan,nan,nan,Core needle biopsy,nan,nan,22.0,nan,nan,nan,nan,nan,nan,nan,nan,nan,nan,nan,nan,VERDADERO,IDC,0:LIVING,Negative,nan,Left,NO,nan,nan,nan,nan,Negative,nan,WHITE,nan,YES,1,Primary,Male,Sentinel lymph node biopsy plus axillary dissection,nan,nan,nan,Modified Radical Mastectomy,A1,733333333.0,TUMOR FREE,Cluster 1
43.0,M0,N3,Stage IIIC,T2,Breast Invasive Lobular Carcinoma,nan,0:DiseaseFree,Allred score = 7,nan,Positive,nan,NOT HISPANIC OR LATINO,nan,199.0,nan,nan,7.1,nan,nan,Positive,nan,nan,nan,nan,Infiltrating Lobular Carcinoma,nan,No,No,C50.9,nan,nan,YES,25.0,nan,36.0,nan,Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement),nan,nan,NO,Core needle biopsy,nan,NO,12.0,nan,nan,nan,nan,nan,nan,nan,nan,nan,nan,nan,nan,FALSO,ILC,0:LIVING,Positive,nan,Right,NO,nan,nan,Allred score = 8,nan,Positive,nan,WHITE,nan,YES,1,Primary,Female,Axillary lymph node dissection alone,nan,nan,nan,Modified Radical Mastectomy,E2,4.0,TUMOR FREE,Cluster 1
45.0,M0,N1,Stage IIB,T2,Invasive Breast Carcinoma,nan,0:DiseaseFree,Allred score = 5,nan,Positive,nan,NOT HISPANIC OR LATINO,nan,269.0,nan,nan,15.12,nan,nan,Positive,70-79%,2.0,nan,nan,Infiltrating Ductal Carcinoma,nan,No,No,C50.9,Equivocal,nan,YES,1.0,nan,6.0,nan,Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy),nan,nan,NO,Tumor resection,nan,NO,16.0,nan,nan,nan,nan,nan,nan,nan,nan,nan,nan,nan,nan,VERDADERO,BRCA,0:LIVING,Negative,nan,Left Upper Outer Quadrant,NO,Allred score 2+2 = 4,nan,Allred score = 4,nan,Positive,nan,WHITE,nan,YES,1,Primary,Female,Sentinel node biopsy alone,nan,nan,nan,Lumpectomy,E2,533333333.0,TUMOR FREE,Cluster 1
